Background: Linear scars, resulting from surgical incisions or traumatic injuries, can pose both aesthetic and functional dilemmas. Ablative fractional CO₂ laser (AFCL) therapy has been recognized for its ability to enhance the appearance and flexibility of scars; however, the ideal timing for such treatments remains a subject of debate.
Aims: This study retrospectively evaluates the effectiveness of AFCL in treating linear atrophic and hypertrophic scars, with a focus on identifying the optimal timing to achieve the best possible outcomes.
Methods: Patients who underwent treatment for linear scars using AFCL at our hospital between January 2022 and July 2024 were included in the study. Participants were categorized into two groups: those with atrophic scars and those with hypertrophic scars. Hypertrophic scars were assessed using the Vancouver Scar Scale (VSS), whereas atrophic scars were evaluated with the Scar Cosmesis Assessment and Rating (SCAR) scale. Furthermore, considering the timing of scar formation-with a six-month period as the threshold-two subgroups were categorized as early treatment and late treatment. The disparities in scar improvement rates were then computed and subjected to analysis.
Results: Among 55 patients, 31 had atrophic scars and 24 had hypertrophic scars. AFCL treatment significantly improved clinical scores in both groups. The SCAR score for atrophic scars decreased from 6.50 (SD 1.31) to 4.92 (SD 1.71) (p < 0.001), and the VSS score for hypertrophic scars decreased from 6.02 (SD 0.46) to 2.73 (SD 0.39) (p < 0.001). The early-treatment subgroup showed a 35.38% (SD 24.54%) improvement in atrophic scars, significantly higher than the 12.53% (SD 25.65%) in the late-treatment subgroup (p = 0.018). No significant timing effect was found for hypertrophic scars (p = 0.764).
Conclusion: AFCL is an effective treatment for linear scars. Early intervention, specifically within the first 6 months, leads to superior outcomes for atrophic scars. In contrast, the timing of treatment is less critical for hypertrophic scars.
Trial Registration: Chinese clinical trial registry: Registration no. ChiCTR2400092038.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11877625 | PMC |
| http://dx.doi.org/10.1111/jocd.70019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fractional carbon dioxide laser treatment of hypertrophic scar clinical and histopathological evaluation.
Lasers Med Sci
March 2025
National Institute of Laser Enhanced Science, Egypt Cairo University, Al Giza, Egypt.
Hypertrophic scar could be associated with several complications that interfere with patient daily activities, physical and psychological health and impact patient quality of life. Several therapeutics and maneuvers are used for treatment of hypertrophic scar with variable success and side effects. We aim to evaluate safety and efficacy of fractional carbon dioxide laser on treatment of hypertrophic scar both clinically and histopathologically.
View Article and Find Full Text PDFLapatinib ameliorates skin fibrosis by inhibiting TGF-β1/Smad and non-Smad signaling pathway.
Sci Rep
March 2025
State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University, Tianjin, China.
Skin fibrosis, characterized by excessive accumulation of extracellular matrix (ECM) in the dermis, can lead to hypertrophic scars and impaired mobility. The ErbB family of receptor tyrosine kinases, including ErbB1 and ErbB2, plays a crucial role in organ fibrosis, but their specific impact on skin fibrosis is less understood. This study investigated the role of ErbB1 and ErbB2 in skin fibrosis and the therapeutic potential of lapatinib, a dual ErbB1 and ErbB2 tyrosine kinase inhibitor.
View Article and Find Full Text PDFFlexible Pressure Sensors for Optimizing Pressure Garment Therapy in Periarticular Scar Treatment: Preclinical and Clinical Applications.
Adv Wound Care (New Rochelle)
March 2025
Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Ninth People's Hospital, Shanghai, People's Republic of China.
Pressure garment therapy is a common strategy for controlling hypertrophic scars; however, insufficient pressure due to reduced elasticity or joint movement limits its effectiveness around joints. The FlexiForce B201 pressure sensor offers precise pressure measurements, thereby demonstrating a promising solution. This study used a Bama pig scar model with an untreated group, a pressure garment group, and a pressure monitoring group that was treated with FlexiForce B201 sensors and pressure garments.
View Article and Find Full Text PDFLessons Learned Evaluating Ablative Fractional CO2 Laser for Burn-Related Donor Site Scars.
J Burn Care Res
March 2025
Firefighters' Burn and Surgical Research Laboratory, MedStar Health Research Institute, Washington, District of Columbia, USA.
Hypertrophic scar (HTS) remains a comorbidity of burn injury, often requiring split thickness skin grafting (STSG) and resulting in symptomatic HTS at grafted sites and STSG donor sites (DS). Literature supports the use of ablative fractional CO2 laser (FLSR) to treat HTS, however many trials lack of control sites and tissue-level examinations. Given the widespread adoption of FLSR for HTS, delegation of non-treated scar sites for the sake of randomized controlled trial (RCT) is troubling for many clinicians.
View Article and Find Full Text PDFEvaluating the combination and comparison of ablative fractional lasers (CO2, Erbium-YAG) with pulsed dye laser (PDL) for treating hypertrophic scars: a systematic review.
Lasers Med Sci
March 2025
Department of Dermatology, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), School of Medicine, Iran University of Medical Sciences, Tehran, Iran, Tehran, Iran, Islamic Republic of.
The aim of this study is to compare pulsed dye laser (PDL) and ablative fractional lasers (CO2, Erbium-YAG) in the treatment of hypertrophic scars in a systematic review. Databases including Web of Science, Science Direct, Google Scholar and PubMed were searched for clinical trials up to December 1, 2022; focusing on the role of ablative fractional lasers and pulsed dye lasers in treating hypertrophic scars, using comprehensive keywords and search syntaxes. Key data extracted included type of scars, the assessment indexes, treatment modalities, side effects and the final conclusion of each article.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!